Praxis Precision Medicines, Inc.
Developing precision medicines for CNS disorders. Relutrigine is under FDA Priority Review for SCN2A/SCN8A developmental and epileptic encephalopathies.
Neurology · Small molecules and antisense oligonucleotides · NDA under FDA Priority Review